Tradegate
08.10.25 | 21:43
4,500 Euro
+0,45 % +0,020
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,460 | 4,560 | 14:43 | |
| 4,460 | 4,580 | 14:20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.09. | Silence Therapeutics plc: Silence Therapeutics to Participate in September Investor Conferences | 342 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate... ► Artikel lesen | |
| 07.08. | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.08. | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 284 | Business Wire | Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV
SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025
Silence... ► Artikel lesen | |
| 07.08. | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
| 27.06. | Silence Therapeutics plc - 8-K, Current Report | 4 | SEC Filings | ||
| 13.06. | H.C. Wainwright reiterates buy rating on Silence Therapeutics stock | 14 | Investing.com | ||
| 12.06. | Silence Therapeutics plc: Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera | 588 | Business Wire | Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded... ► Artikel lesen | |
| 08.05. | Silence Therapeutics plc GAAP EPS of -C$0.20 | 4 | Seeking Alpha | ||
| 08.05. | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 08.05. | Silence Therapeutics plc: Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights | 1.230 | Business Wire | Company further extends cash guidance into 2028
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA)... ► Artikel lesen | |
| 06.05. | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings | ||
| 06.05. | Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors | 525 | Business Wire | Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors
Silence Therapeutics plc... ► Artikel lesen | |
| 30.04. | Silence Therapeutics plc - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 24.04. | Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying | 4 | Insider Monkey | ||
| 05.03. | Silence Therapeutics plc: Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference | 359 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present... ► Artikel lesen | |
| 27.02. | Silence Therapeutics plc: Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 559 | Business Wire | The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST 1 p.m. GMT
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company")... ► Artikel lesen | |
| 13.02. | Silence Therapeutics plc: Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 | 412 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will... ► Artikel lesen | |
| 09.12.24 | Silence Therapeutics plc: Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting | 361 | Business Wire | New divesiran data continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients Silence also announces first subject dosed in Phase 2 study... ► Artikel lesen | |
| 26.11.24 | Silence Therapeutics plc: Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference | 177 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered... ► Artikel lesen | |
| 18.11.24 | Silence Therapeutics plc: Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting | 620 | Business Wire | New zerlasiran data show significant time-averaged Lp(a) reductions with effects persisting 60 weeks following the first dose Represents first study to report time-averaged Lp(a) results to further... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 50,55 | -1,52 % | Puma Aktie: Große Trendwende? - Adidas, Bayer, Enapter, Mutares und Novo Nordisk im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| GILEAD SCIENCES | 101,58 | -0,10 % | Breaking Down Gilead Sciences: 6 Analysts Share Their Views | ||
| VERTEX PHARMACEUTICALS | 361,40 | -0,26 % | What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet? | ||
| INNOCAN PHARMA | 12,100 | -0,82 % | STRONG BUY: InnoCan Rallye - jetzt einsteigen?! | ||
| IONIS PHARMACEUTICALS | 59,82 | -0,60 % | Ionis Pharmaceuticals stock price target raised to $85 from $75 at Raymond James | ||
| SNDL | 2,260 | -0,26 % | SNDL Inc.: SNDL Announces 2025 Annual and Special Meeting Results | EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ: SNDL) (CSE: SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 21,600 | -1,37 % | Assembly Biosciences: Mega-Daten und Investoren-Ansturm | Es geht Schlag auf Schlag: Heute Morgen erst hatte ich über die neuesten, positiven Entwicklungen bei Assembly Biosciences berichtet, schon folgen die nächsten Kracher, die für ein neues Kurshoch sorgen.... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,870 | +1,16 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces New Franchise Agreement and Real Estate Signed for Heal Wellness in Cochrane, Alberta | Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 385,10 | -0,64 % | 27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know | ||
| LIGAND PHARMACEUTICALS | 156,00 | -1,89 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,034 | -100,00 % | Promino Nutritional Sciences, Inc.: Promino Nutritional Sciences Inc. Announces Change of Director and Officer | Burlington, Ontario--(Newsfile Corp. - September 8, 2025) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC Pink: MUSLF) (FSE: 93X) (the "Company" or "Promino") is pleased to announce that Moira... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,280 | 0,00 % | Daré Bioscience Receives $4 Mln Grant Funding For Smart Contraceptive Program | ||
| HYTN INNOVATIONS | 0,092 | 0,00 % | HYTN sichert sich Cannabis-Arzneimittellizenz und erzielt Fortschritte im Zulassungsverfahren für verschreibungspflichtige Arzneimittel für Medikamente auf Cannabinoidbasis | Vancouver, British Columbia - 14. Juli 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
führendes Unternehmen in der Herstellung... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 2,220 | -1,77 % | TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 6,250 | -0,79 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency | Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) ... ► Artikel lesen |
SILENCE THERAPEUTICS PLC ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,020 (+0,45 %) liegt der Kurs bei 4,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.